Cullinan Therapeutics reports Q3 results
At a glance
- $CGEM today−2.37%last $9.28
- Vs industry peers−2.56 pts6-peer median +0.19% · far behind
- Since Nov 10−16.6%from the first trade after the story
- 52-week range12.7% above low$8.23 – $23.19
- Cash runway~6 mo$88.3M cash ÷ $14.2M/mo burn · 10-Q
- Coverage0 this week1 in 30 days · too few stories to call a pace
Nothing reported about cullinan across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: Earnings reports are less about the numbers and more about how they stack up against expectations — and what the company says next often holds more weight.
- How the stock is trading: $CGEM -2.37% in the latest session.
- Timing: It was published while New York was trading, so the day's move may already include the first reaction.
Where the stock stands
Cullinan Therapeutics ($CGEM) declined 2.37% to $9.28 in the latest session. Over the past month it is down 33.7%. That leaves it 60% below its 52-week high of $23.19 and 13% above its low of $8.23, close to the bottom of its range. It has been a volatile year: the high was 2.8 times the low, so moves this size are not unusual for it.
What the filings say
In its latest report (10-Q, filed Nov 10, 2026), $CGEM lost $49.4M over the quarter to Sep 30, 2026. Operations used $127.3M of cash over the nine months to Sep 30, 2026 — about $14.2M a month — against $88.3M in cash on Sep 30, 2026. At that pace the cash covers about 6 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. Total liabilities were $41.3M against $88.3M of cash on Sep 30, 2026. The company filed an 8-K — the form for material events — on Nov 10, the same day as this story; it is $CGEM's own account and the first thing to read. Figures are as filed with the SEC; the $CGEM page has the full statements.
How much coverage it is getting
Wook has no other story on Cullinan Therapeutics from the last 30 days, so there is no recent run to compare this one with.
The bigger picture
Even if a company beats estimates, a lackluster outlook can leave investors cold, showing that guidance can be more telling than the actual results. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
What to watch next
The $CGEM page has all the charts, filings, and models to back up every figure. Reading multiple outlets on the same story helps spot confirmation or repetition. Wook AI can pull live data and run the numbers on request — like how far $CGEM is from its high or how this week's coverage stacks up.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Seeking Alpha published this on November 10, 2026. $CGEM has moved -16.63% ($11.13 to $9.28). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
